Importantly, subgroup analyses stratified by BRCA mutation type (BRCA1 vs. BRCA2) and tumor biology (triple-negative vs. hormone receptor-positive) confirmed these findings, supporting the applicability of BCS across biologically distinct subgroups within the BRCA-mutated population. This evidence concerns the gene BRCA1 and neoplasm.